Lucid Diagnostics(LUCD) Prnewswire·2025-03-27 12:01Core Insights - Lucid Diagnostics Inc. has launched a campaign titled "Embrace the Future" to promote its EsoCheck® Esophageal Cell Collection Device, coinciding with Esophageal Cancer Awareness Month and the upcoming Digestive Disease Week (DDW) Conference [1] - The EsoCheck device has demonstrated outstanding performance in nearly 30,000 patients, showcasing a pristine safety record and high patient satisfaction, with a procedure time of less than three minutes [2] - EsoCheck, when used with Lucid's EsoGuard® Esophageal DNA Test, has achieved an unprecedented negative predictive value (NPV) of approximately 99% in detecting esophageal precancer [2] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [4] - The company's EsoGuard® Esophageal DNA Test, performed on samples collected via the EsoCheck device, is the first and only commercially available tool aimed at preventing cancer through early detection of esophageal precancer in at-risk patients [4] Industry Context - Esophageal Cancer Awareness Month serves as a reminder of the approximately 16,000 annual deaths in the U.S. due to esophageal cancer, which is now considered preventable with modern technologies [3] - The traditional "sponge-on-a-string" (SOS) devices used for cell collection have been criticized for their poor performance and safety issues, leading to multiple FDA recalls, while EsoCheck offers a targeted and safe alternative [3]